enGene (ENGN) Competitors $3.70 +0.01 (+0.27%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$3.70 +0.00 (+0.14%) As of 07/25/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENGN vs. KALV, OCS, ANAB, AVBP, VIR, IOVA, AMLX, SION, CRMD, and TNGXShould you be buying enGene stock or one of its competitors? The main competitors of enGene include KalVista Pharmaceuticals (KALV), Oculis (OCS), AnaptysBio (ANAB), ArriVent BioPharma (AVBP), Vir Biotechnology (VIR), Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals (AMLX), Sionna Therapeutics (SION), CorMedix (CRMD), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry. enGene vs. Its Competitors KalVista Pharmaceuticals Oculis AnaptysBio ArriVent BioPharma Vir Biotechnology Iovance Biotherapeutics Amylyx Pharmaceuticals Sionna Therapeutics CorMedix Tango Therapeutics KalVista Pharmaceuticals (NASDAQ:KALV) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation. Do analysts recommend KALV or ENGN? KalVista Pharmaceuticals currently has a consensus price target of $26.29, indicating a potential upside of 80.29%. enGene has a consensus price target of $23.29, indicating a potential upside of 529.34%. Given enGene's higher probable upside, analysts clearly believe enGene is more favorable than KalVista Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11enGene 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in KALV or ENGN? 64.2% of enGene shares are owned by institutional investors. 10.5% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 10.4% of enGene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is KALV or ENGN more profitable? enGene's return on equity of -32.60% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets KalVista PharmaceuticalsN/A -134.07% -82.65% enGene N/A -32.60%-28.26% Which has more risk & volatility, KALV or ENGN? KalVista Pharmaceuticals has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.42, suggesting that its share price is 142% less volatile than the S&P 500. Which has better valuation and earnings, KALV or ENGN? KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalVista PharmaceuticalsN/AN/A-$183.44M-$3.69-3.95enGeneN/AN/A-$55.14M-$1.65-2.24 Does the media prefer KALV or ENGN? In the previous week, enGene had 1 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 8 mentions for enGene and 7 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.68 beat enGene's score of -0.30 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KalVista Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Neutral SummaryenGene beats KalVista Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get enGene News Delivered to You Automatically Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENGN vs. The Competition Export to ExcelMetricenGeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$188.58M$3.05B$5.70B$9.50BDividend YieldN/A2.37%4.58%4.00%P/E Ratio-2.2421.3228.3920.08Price / SalesN/A280.80430.0899.95Price / CashN/A42.7636.2258.56Price / Book0.698.378.675.88Net Income-$55.14M-$55.19M$3.25B$258.89M7 Day Performance-2.37%5.86%4.30%3.70%1 Month Performance3.06%17.29%10.57%11.71%1 Year Performance-58.89%4.39%35.68%17.98% enGene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENGNenGene2.8244 of 5 stars$3.70+0.3%$23.29+529.3%-58.9%$188.58MN/A-2.2431KALVKalVista Pharmaceuticals3.9579 of 5 stars$15.56+1.1%$26.29+68.9%+1.3%$768.79MN/A-4.22100OCSOculis2.2461 of 5 stars$17.50flat$35.33+101.9%+54.7%$764.09M$780K-6.632ANABAnaptysBio1.8926 of 5 stars$26.17+1.0%$42.38+61.9%-27.6%$761.53M$111.87M-5.40100News CoveragePositive NewsAnalyst ForecastAVBPArriVent BioPharma2.1419 of 5 stars$21.55-2.3%$39.29+82.3%+0.2%$754.39MN/A-5.7240Analyst ForecastAnalyst RevisionVIRVir Biotechnology3.5237 of 5 stars$5.52+2.0%$30.25+448.0%-47.0%$747.87M$74.21M-1.31580News CoverageIOVAIovance Biotherapeutics4.6218 of 5 stars$2.49+11.7%$12.22+390.9%-66.8%$744.67M$212.68M-2.01500Analyst ForecastOptions VolumeGap UpHigh Trading VolumeAMLXAmylyx Pharmaceuticals3.1408 of 5 stars$8.21-1.6%$11.75+43.1%+324.5%$743.44M$87.37M-2.64200SIONSionna TherapeuticsN/A$17.44+4.2%$38.50+120.8%N/A$738.64MN/A0.0035Positive NewsCRMDCorMedix2.7788 of 5 stars$10.94+0.7%$17.14+56.7%+143.9%$736.58M$43.47M49.7330TNGXTango Therapeutics1.895 of 5 stars$6.77flat$10.50+55.1%-30.8%$733.83M$42.07M-5.5590Positive News Related Companies and Tools Related Companies KALV Competitors OCS Competitors ANAB Competitors AVBP Competitors VIR Competitors IOVA Competitors AMLX Competitors SION Competitors CRMD Competitors TNGX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENGN) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENGN Stock Alerts